Stock Events

Stock Events

Metagenomi Therapeutics 

$1.1700
64
+$0.01+0.86% Friday 20:00
+$0.00+0%Friday 23:48After hours

Statistics

Day High
1.165
Day Low
1.16
52W High
3.95
52W Low
1.128
Volume
941
Avg. Volume
-
Mkt Cap
44.2M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.75
-0.62
-0.5
-0.37
Expected EPS
-0.639496
Actual EPS
N/A

Financials

-348.54%Profit Margin
Unprofitable
2021
2022
2023
2024
2025
25.21MRevenue
-87.87MNet Income

Analyst Ratings

7.00Average Price Target
The highest estimate is 9.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MGX. It's not an investment recommendation.
NVIDIA
17
NVDA
Alphabet
15
GOOGL
AMD
15
AMD
Amazon
14
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is a leader in the development of gene editing technologies, directly competing with Metagenomi's gene editing platforms.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine focuses on developing CRISPR gene editing treatments, making it a direct competitor in the gene therapy space.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is known for its advancements in CRISPR/Cas9 technology for gene editing, competing in the same field as Metagenomi.
Beam Therapeutics
BEAM
Mkt Cap3.03B
Beam Therapeutics uses base editing, a form of gene editing that competes with Metagenomi's gene editing approaches.
Vir Biotechnology
VIR
Mkt Cap1.83B
Vir Biotechnology works on gene editing and therapy for treating infectious diseases, positioning it as a competitor in the gene therapy field.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, which, while not directly gene editing, competes in the broader genetic medicine space.
Pacific Biosciences of California
PACB
Mkt Cap435.16M
Pacific Biosciences offers gene sequencing technology, which is foundational for gene editing research and development, indirectly competing with Metagenomi.

About

Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
Show more...
CEO
Jian Irish
Employees
113
Country
United States
ISIN
US59102M1045

Listings

XNAS
US
MGX
BOATS
BOATS
MGX.BOATS

0 Comments

Share your thoughts

FAQ

What is Metagenomi Therapeutics stock price today?▼
The current price of MGX is $1.17 USD — it has increased by +0.86% in the past 24 hours. Watch Metagenomi Therapeutics stock price performance more closely on the chart.
What is Metagenomi Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Metagenomi Therapeutics stocks are traded under the ticker MGX.
Is Metagenomi Therapeutics stock price growing?▼
MGX stock has fallen by -1.68% compared to the previous week, the month change is a -3.7% fall, over the last year Metagenomi Therapeutics has showed a -38.74% decrease.
What is Metagenomi Therapeutics market cap?▼
Today Metagenomi Therapeutics has the market capitalization of 44.2M
When is the next Metagenomi Therapeutics earnings date?▼
Metagenomi Therapeutics is going to release the next earnings report on November 18, 2026.
What were Metagenomi Therapeutics earnings last quarter?▼
MGX earnings for the last quarter are -0.73 USD per share, whereas the estimation was -0.55 USD resulting in a -31.99% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Metagenomi Therapeutics revenue for the last year?▼
Metagenomi Therapeutics revenue for the last year amounts to 25.21M USD.
What is Metagenomi Therapeutics net income for the last year?▼
MGX net income for the last year is -87.87M USD.
How many employees does Metagenomi Therapeutics have?▼
As of September 05, 2026, the company has 113 employees.
In which sector is Metagenomi Therapeutics located?▼
Metagenomi Therapeutics operates in the Health & Wellness sector.
When did Metagenomi Therapeutics complete a stock split?▼
Metagenomi Therapeutics has not had any recent stock splits.
Where is Metagenomi Therapeutics headquartered?▼
Metagenomi Therapeutics is headquartered in EMERYVILLE, United States.